The Oncology Institute, Inc. (NASDAQ:TOI) Given Consensus Recommendation of “Moderate Buy” by Brokerages

by · The Markets Daily

The Oncology Institute, Inc. (NASDAQ:TOI – Get Free Report) has been given a consensus rating of “Moderate Buy” by the six analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $8.20.

Several analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncology Institute in a research report on Monday, April 20th. Lake Street Capital initiated coverage on Oncology Institute in a research note on Monday. They set a “buy” rating and a $10.00 price target for the company. B. Riley Financial lifted their price target on Oncology Institute from $6.00 to $8.00 and gave the company a “buy” rating in a report on Friday, March 13th. Needham & Company LLC raised their price target on shares of Oncology Institute from $5.00 to $7.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. Finally, BTIG Research lifted their price objective on shares of Oncology Institute from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, June 8th.

Check Out Our Latest Stock Analysis on Oncology Institute

Oncology Institute Price Performance

TOI traded up $0.28 on Monday, reaching $5.56. 122,714 shares of the company traded hands, compared to its average volume of 1,888,124. The company has a market cap of $549.85 million, a price-to-earnings ratio of -14.89 and a beta of 0.36. The stock’s 50 day moving average price is $4.57 and its 200-day moving average price is $3.66. Oncology Institute has a 52-week low of $2.32 and a 52-week high of $5.82.

Oncology Institute (NASDAQ:TOI – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. The company had revenue of $147.44 million during the quarter, compared to analysts’ expectations of $142.10 million. As a group, equities research analysts forecast that Oncology Institute will post -0.17 earnings per share for the current fiscal year.

Insider Buying and Selling at Oncology Institute

In other news, insider Yale Podnos sold 23,451 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $5.38, for a total transaction of $126,166.38. Following the completion of the sale, the insider owned 259,527 shares in the company, valued at approximately $1,396,255.26. This represents a 8.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mohit Kaushal sold 57,286 shares of the stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $3.50, for a total value of $200,501.00. Following the transaction, the director directly owned 211,016 shares in the company, valued at approximately $738,556. This represents a 21.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have purchased 118,500 shares of company stock worth $488,655 and have sold 119,170 shares worth $461,183. Corporate insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Oncology Institute

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Oncology Institute by 6.2% during the third quarter. Vanguard Group Inc. now owns 4,545,245 shares of the company’s stock valued at $15,863,000 after purchasing an additional 264,358 shares during the last quarter. CenterBook Partners LP boosted its holdings in shares of Oncology Institute by 12.0% during the 4th quarter. CenterBook Partners LP now owns 3,029,312 shares of the company’s stock worth $10,784,000 after buying an additional 324,662 shares during the period. Kanen Wealth Management LLC boosted its holdings in shares of Oncology Institute by 61.6% during the 4th quarter. Kanen Wealth Management LLC now owns 2,976,144 shares of the company’s stock worth $10,712,000 after buying an additional 1,134,043 shares during the period. Balyasny Asset Management L.P. grew its stake in Oncology Institute by 17.3% in the 2nd quarter. Balyasny Asset Management L.P. now owns 2,518,337 shares of the company’s stock valued at $5,163,000 after buying an additional 371,005 shares during the last quarter. Finally, Josh Arnold Investment Consultant LLC grew its stake in Oncology Institute by 1,104.3% in the 4th quarter. Josh Arnold Investment Consultant LLC now owns 2,459,809 shares of the company’s stock valued at $8,757,000 after buying an additional 2,255,559 shares during the last quarter. Institutional investors own 36.86% of the company’s stock.

Oncology Institute Company Profile

(Get Free Report)

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.

Featured Articles